Literature DB >> 29020481

Ocular Toxoplasmosis in Tropical Areas: Analysis and Outcome of 190 Patients from a Multicenter Collaborative Study.

Philemon K Huang1, Chen Jianping1, Daniel Vitor Vasconcelos-Santos2, Jacqueline Souza Dutra Arruda2, Parthopratim Dutta Majumder3, Eliza Anthony3, Sudha K Ganesh3, Jyotirmay Biswas3, Ho Su Ling1, Stephen C Teoh4, Rupesh Agrawal1.   

Abstract

PURPOSE: To describe clinical findings and outcomes for ocular toxoplasmosis in an international multicenter collaborative study.
METHODS: Retrospective analysis of 190 patients diagnosed with ocular toxoplasmosis from three study sites (Brazil, India, and Singapore).
RESULTS: There were 93 (48.9%) females with a mean age of 32.8 years. The most common symptoms were isolated blurring of vision (36.8%), followed by blurring of vision with floaters (21.1%). Treatment regimens varied largely from monotherapy to multiple combination therapies. Final visual acuity of ≥20/40 was achieved in 106 (74.2%) patients. In a median follow-up period of 31 weeks (range 12-749 weeks), 83/190 (43.7%) patients suffered a relapse.
CONCLUSIONS: There appears to be geographical variation in the presentation of ocular toxoplasmosis. Compared to previous studies, we did not observe the '"dual peak" phenomenon of chronic and active disease based on age at presentation, and there was less bilateral and macular involvement (but more peripheral involvement).

Entities:  

Keywords:  Epidemiology; multicenter collaborative study; ocular toxoplasmosis; therapy; uveitis

Mesh:

Substances:

Year:  2017        PMID: 29020481     DOI: 10.1080/09273948.2017.1367407

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  1 in total

Review 1.  Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis.

Authors:  John E Feliciano-Alfonso; Juliana Muñoz-Ortiz; María Alejandra Marín-Noriega; Andrés Vargas-Villanueva; Laura Triviño-Blanco; Natalia Carvajal-Saiz; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.